IGM Biosciences, Inc. has announced that it has entered into a definitive merger agreement with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire IGM Biosciences for $1.247 in cash per share, along with a non-tradeable contingent value right $(CVR)$. This CVR entitles holders to receive 100% of any closing net cash exceeding $82.0 million, and 80% of net proceeds from certain dispositions of IGM Biosciences' product candidates and intellectual property within one year post-closing. The transaction, which has received unanimous approval from the IGM Biosciences Board of Directors, is expected to close in August 2025 following a tender offer scheduled by July 16, 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。